688756-15-2

Upstream product

• 688756-14-1 (2R,5R)-2-tert-butyl-3-(3,5-dichloro-phenyl)-5-methyl-1-(2,2,2-trifluoro-acetyl)-5-(4-trifluoromethoxy-benzyl)-imidazolidin-4-one 
• 1246745-48-1 (2R,5R)-5-(4-trifluoromethoxybenzyl)-3-(3,5-dichlorophenyl)-2-isopropyl-5-methyl-1-(2,2,2-trifluoroacetyl)-imidazolidin-4-one 

Downstream Products

• 688756-16-3 (R)-3-(3,5-dichloro-phenyl)-5-methyl-2-thioxo-5-(4-trifluoromethoxy-benzyl)-imidazolidin-4-one 
• 1175561-69-9 (R)-2-amino-3-(4-trifluoromethoxyphenyl)-N-(3,5-dichlorophenyl)-2-methylpropionamide p-toluenesulfonic acid salt 
• 1356585-14-2 (2R)-N-(3,5-dichlorophenyl)-2-(2,2-dimethoxyethyl[14(C)]carbamoylamino)-2-methyl-3-[4-(trifluoromethoxy)phenyl]propanamide 

Relevant academic research and scientific papers

Efficient synthesis of a small molecule, nonpeptide inhibitor of LFA-1

Figure Presented. A three-stage process for the synthesis of LFA-1 inhibitor 1 from amine 4 with an overall yield of 65% is described. The key stage involves a Ph3PCl2-induced dehydration/cyclization of urea 6 followed by a regiosele

Synthesis of 6,7-Dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides

Disclosed is an improved multi-step process for preparing a compound of Formula I: wherein R1 to R3 are as defined herein. The compounds of formula I inhibit the binding of human intercellular adhesion molecules to the Leukointegrins

Synthesis of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides

Disclosed is a multi-step process for preparing a compound of Formula I: wherein R1 to R3 are as defined herein. The compounds of formula I inhibit the binding of human intercellular adhesion molecules to the Leukointegrins. As a res

DERIVATIVES OF [6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-SULFONYLAMINO]-PROPIONAMIDE

Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

DERIVATIVES OF [6,7-DIHYDRO-5H-IMIDAZO[1,2-A]IMIDAZOLE-3-SULFONYL]-PYRROLIDINE-2-CARBOXYLIC ACID AMIDE

Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease